• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enlivex Therapeutics Ltd (NQ: ENLV )

    1.360 +0.010 (+0.74%)
    Streaming Delayed Price Updated: 3:55 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Enlivex Therapeutics Ltd

    < Previous 1 2 3 4 5 Next >
    Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
    Via ACCESSWIRE
    Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)
    Via AB Newswire
    Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    Nasdaq Jumps 250 Points; Crude Oil Down 1%
    U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83.... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
    Via Benzinga
    Dow Dips 100 Points; CarMax Earnings Miss Views
    U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday. 
    Via Benzinga
    Topics Earnings Stocks
    Exposures Financial US Equities
    Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
    U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94.... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
    ENLV stock results show that Enlivex Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
    Via ACCESSWIRE
    Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
    Via ACCESSWIRE
    Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
    From Enlivex Therapeutics Ltd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.